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doi:10.1016/j.jds.2011.05.006Abstract Background/purpose: Oral squamous cell carcinoma (OSCC) is the fourth major
cause of mortality among males in Asia. The tumorigenesis of OSCC is a multi-step process
characterized by sequential morphological changes. The extent of lymph node metastasis is
a major determinant in the prognosis of cancer. Hypermethylation is an important pathway
for repression of gene transcription in cancer cells and a promising marker for cancer detec-
tion. It is also found in early metastatic cancer patients.
Materials and methods: Sixty-four histologically confirmed OSCC tissues and corresponding non-
tumorous tissueswereenrolled in this study. DNAwasextracted. Thepromotermethylation status
of thep16, death-associated protein kinase (DAPK), MGMT, and glutathione S-transferase genes in
OSCC tissues was evaluated by a methylation-specific polymerase chain reaction analysis.
Results: Frequencies of promoter hypermethylation of p16, DAPK, and MGMT in OSCC tissue were
67.2%, 45.3%, and 31.3%, respectively. No methylation was found in normal oral mucosa. Meth-
ylation rates of MGMT (50%) and DAPK (55.6%) in metastasized OSCC were higher than those of
MGMT (23.9%) and DAPK (41.3%) in nonmetastasized OSCC. No glutathione S-transferase P meth-
ylation was found in any tissue samples.
Conclusions: Our study supports the hypothesis that hypermethylation of p16 gene promoters
may indicate a high risk of oral cancer, and hypermethylation of the MGMT and DAPK genes
may be a major indicator of early OSCC metastasis.
Copyright ª 2011, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.of Oral and Maxillofacial Surgery, MacKay Memorial Hospital, No. 92, Section 2 Chung San N Road,
433535; fax: þ886 2 25433642.
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Oral squamous cell carcinoma (OSCC) is the fourth major
cause of mortality among men in Taiwan and its incidence
rates continue to rise annually.1 OSCC is closely associated
with tobacco consumption and the chewing of betel nut
(Areca catechu), which is widely available on the island.
Two-thirds of OSCC patients in Taiwan seek medical treat-
ment at an advanced stage.2 Despite some progress in OSCC
treatments (surgery is still the primary treatment), the
overall 5-year survival rate for OSCC patients is 50%, which
has not significantly changed over the past 2 decades.3 It
was estimated that 20e50% of patients without clinically
evident cervical lymph node metastases do in fact have
microscopic metastases, which lead to poor prognoses.4
It is, therefore, important to identify new diagnostic
approaches and therapeutic targets for this deadly disease.
Efforts to identify novel molecular predictors of behavior
and therapeutic targets for OSCC have reported close
relationships between several genetic and epigenetic
alterations and the progressive development of OSCC.5e8
Aberrant methylation of CpG islands in gene promoters is
a common mechanism for suppressing gene expression in
cancer cells. A process known as cytosine methylation can
turn off the expressions of tumor-suppressor genes, just
like a light switch, leading to oral cancer.9e14
Silencing of cancer-associated genes by hypermethylation
of CpG islands within the promoter and/or 50-regions of many
genes is a common feature of human cancer and is often
associatedwitha transcriptional blockand lossof the relevant
protein, which is analogous to genetic loss-of-function
mutations, such as point mutations and deletions.15,16
Hypermethylation of the promoters of cancer-related genes
is often associated with tumorigenesis and may also be
involved inmetastasis.17e21 Previous studies ofOSCC reported
the hypermethylation of several genes involved in DNA repair
[O6-methylguanine-DNA-methyltranferase (MGMT)], tumor
suppression (p16), detoxification of xenobiotics [glutathione
S-transferase P (GSTP1)], and apoptosis-related gene [death-
associated protein kinase (DAPK)].22e24
Although a consensus has emerged on hypermethylation,
present studies disagree on methylation rates.24e32 Thus,
two important questions are in order: to what degree does
CpG island hypermethylation contribute to the genomic
abnormalities in OSCC in Taiwan; and do hypermethylation
events accumulate as cells progress toward metastasis? To
detect the presence of neoplastic DNAmethylation, we used
a real-time quantitative methylation-specific polymerase
chain reaction (MS-PCR) to analyze promoter hyper-
methylation rates of the p16, DAPK, MGMT, and GSTP1 genes
in 64 OSCC tumors and corresponding adjacent normal
mucosa. Twenty normal gingival mucosal samples obtained
from healthy persons, who did not smoke or chew betel nut,
served as a control group.
Materials and methods
Subjects
This study was approved by the institutional review board
of Taichung Veterans General Hospital, Taichung, Taiwan.Sixty-four histologically confirmed OSCC tissues and corre-
sponding nontumorous tissues were randomly obtained
from patients in 1997e2004 from the Oral Maxillofacial
Surgery Section of Taichung Veterans General Hospital. The
detailed clinical data, including site and differentiation of
the tumor and patient habits were carefully documented.
Twenty healthy oral mucosa samples of the third molar
region were obtained from patients who received impacted
wisdom-tooth extraction. All samples were collected in
accordance with institutional guidelines for the protection
of human subjects. Fresh tumors obtained from surgical
resection were immediately stored in liquid nitrogen until
DNA extraction.
DNA extraction and purification
A tissue pellet was placed in genomic DNA isolation reagent
(GenoType, Nehren, Baden-Wu¨rttemberg, Germany) with
proteinase K (0.5 mg/mL) at 50C for 24 hours. Digested
samples were subjected to DNA extraction using the Wizard
Genomic DNA kit according to the protocol of the manu-
facturer (Promega, Madison, WI, USA).
Bisulfite treatment
DNA from tissue specimens was subjected to bisulfite
treatment, as described previously.24,33e35 Briefly, 2 mg of
genomic DNA was re-suspended in 50 mL of water and
denatured in 0.2M NaOH for 10 minutes at 37C. The
denatured DNA was diluted in 550 mL of a freshly prepared
solution containing 10 mM hydroquinone (Sigma, St Louis,
MO, USA) and 3M sodium bisulfite (Sigma; pH 5.0). The DNA
solution was covered with mineral oil and incubated for
16 hours at 50C. After incubation, the DNA sample was
desalted through a column (Wizard DNA Clean-Up System,
Promega), treated with 0.3M NaOH for 5 minutes at room
temperature, and precipitated with ethanol. The bisulfite-
modified genomic DNA was resuspended in 20 mL H2O and
used immediately or stored at 70C.
Methylation-specific polymerase chain reaction
(MS-PCR)
The modified DNA served as a template for PCR amplifica-
tion using primers specific for either methylated or modi-
fied unmethylated DNA. Because bisulfite treatment
converts unmethylated cytosine to uracil while leaving
methylated cytosine intact, specific primers were designed
to accommodate these changes (Table 1). For the PCR
amplification, 2 mL of bisulfite-modified DNA was added to
a final volume of 25 mL PCR mix containing 1 unit FastStart
Taq polymerase (Roche, California,USA), 1x PCR buffer,
2mM MgCl2, 0.2mM dNTPs, and a primer (5mM each per
reaction). All PCR amplifications were performed in a Pelt-
ier Thermal cycler (MJ Research, Massachusetts, USA).
Reactants were first incubated at 95C for 5 minutes, fol-
lowed by 35 cycles of 95C for 50 seconds, the specific
annealing temperature for each gene for 50 seconds, and
72C for 50 seconds, followed by a final 10-min extension
at 72C.25 PCR products were directly loaded onto
Table 1 Gene primer sequences.
Gene Primer sequences Annealing
temperature
p16 U 50-TTATTAGAGGGTGGGGTGGATTGT30(sense) 50-CAAACCCCAAACCACAACCATAA30(antisense) 60C
M 50-TTATTAGAGGGGTGGGGGCGATCGC30(sense) 50-ACCCCCGAACCGCGACCGTAA30(antisense) 65C
GSTP1 U 50-CCACCCCCAATACTAAATCACAACA30(sense) 50-CCACCCCAATACTAAATCACAACA30(antisense) 59C
M 50-TTCGGGGTGTAGCGCTCGTC30(sense)
50-GCCCCAATACTAAATCACGACG30(antisense)
59C
DAPK U 50-GGAGGATAGTTGGATTGATTGGTTAATGTT30(sense) 50-CAAATCCCTCCCAAACACCAA30(antisense) 60C
M 50-GGATAGTCGGATCGAAGTTAACGTC30(sense) 50-CCCTCCCAAACGCCGA30(antisense) 60C
MGMT U 50-TTTGTGTTTTGATGTTTGTAGGTTTTTGT30 (sense) 50-AACTCCACACTCTTCCAAAAACAAACA
30(antisense)
59C
M 50-TTCGACGTTCGTAGGTTTTCGC30 (sense) 50-GCACTCTTCCGAAAACGAAACG 30(antisense) 59C
DAPK Z death-associated protein kinase; MGMT Z O6-methylguanine-DNA-methyltranferase.
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visualized under UV illumination.
Statistical analysis
Statistical analyses were performed using SPSS software
(SPSS, Chicago, IL, USA). The associations between the
variables were assayed by a Chi-squared test. A P value of
<0.05 was considered statistically significant.
Results
Clinicopathological findings
The 64 Taiwan OSCC patients consisted of 58 men and 6
women, whose ages ranged 26e77 (mean, 51.7 years) years.
Tumor sites included the oral buccal mucosa (n Z 32),
tongue (n Z 24), and others (n Z 8). The patients’ patho-
logical stages included 4 cases of Stage I, 9 cases of Stage II,
17 cases of Stage III, and 34 cases of Stage IV. Histopatho-
logically, tumors were classified as 6 well-differentiated
carcinomas, 18 well-to-moderately differentiated carci-
nomas, 34 moderately-differentiated carcinomas, and 6
moderately-to-poorly differentiated carcinomas. Neck
lymph metastasis was noted in 18 cases. Fifty betel-nut
chewers had histories of daily consumption of more than
10 areca nuts for more than 10 years.
Methylation findings
Sixty-four OSCC tissues and corresponding nontumorous
tissues and 20 healthy normal mucosa tissues were assem-
bled for this study. DNA was extracted from each specimen
and the methylation status of the p16, MGMT, DAPK, and
GSTP1 gene promoters was analyzed by MS-PCR. Results are
shown in Fig. 1.
The proportions of promoter methylation of genes in this
study were calculated as a percentage of the test sample.
No methylation was noted in normal mucosal samples.
Aberrant methylation of at least one of these genes was
detected in 60 (94.0%) of 64 OSCC tissues and in 45 (70.3%)
of 64 corresponding nontumorous tissues. Methylation
of the detoxifier gene, GSTP1, was not present in OSCCtissues. The tumor-suppressor gene, MGMT, was hyper-
methylated in 31.3% of the OSCC tissues and in 25% of the
corresponding nontumorous tissues. This indicates a higher
percentage of MGMT methylation in tumors than in normal
tissue. Methylation of the p16 and DAPK promoters was
respectively observed in 67.2% and 45.3% of the OSCC tissue
and in 31.3% and 40.6% of the corresponding nontumorous
tissues. The disparity in p16 methylation rates between
carcinoma tissues and corresponding nontumorous tissue
was statistically significant (Table 2A).
Correlation with clinicopathological data
According to the clinical data we obtained, frequencies of
p16, DAPK, and MGMT gene promoter hypermethylation did
not differ based on the tumor site (P > 0.05). Methylation
rates of the p16, DAPK, and MGMT promoter genes in OSCC
tissues were 75%, 43.8%, and 25% for the buccal mucosa and
62.5%, 62.5%, and 37.5% for the tongue, respectively.
Promoter hypermethylation rates of the p16, DAPK, and
MGMT genes were not correlated with tumor size, differ-
entiation, betel nut chewing, tobacco smoking, or alcohol
consumption (P > 0.05) (Table 3).
A comparison of the percentages of methylation of
nonmetastatic and metastatic primary tumors is shown in
Table 2B. Our study found that the following difference was
statistically significant: nonmetastatic primary tumors had
lower percentages of MGMT and DAPK methylation than
metastatic primary tumors. The percentages for the latter
were 50.0 and 55.6, whereas those of the former were only
23.9 and 41.3. Hypermethylated p16 promoters were found
in 63% of nonmetastasized tumors and in 77.8% of meta-
static tumors (but was not statistically significant).
Discussion
Methylation is the main epigenetic modification in humans
and changes in methylation patterns play important roles in
tumorigenesis and metastasis. The MS-PCR technique
enables precise mapping of methylation patterns in CpG
islands of genomic DNA. This study found higher frequen-
cies of overall hypermethylation in three genes (p16,
MGMT, and DAPK) in primary tumors of oral cancer tissues
Figure 1 Representative MSP analysis of p16 (A), DAPK (B), MGMT (C), and GSTP1 (D) genes in oral cancer tissue. The left hand
lane was Gen50 DNA ladder (GeneMark) as a molecular weight marker. The presence of a visible polymerase chain reaction product
in Lanes M indicates the presence of methylated genes, and the amplicons in lanes U indicate presence of unmethylated alleles.
Number represents patient case. N: corresponding normal tissue. T: tumor tissue. OC2: Oral cancer cell line. ME: melanoma cell
line. Oral cancer cell line was used as the positive control. H2O: water was used as a negative control. MSP analysis of all genes had
negative and positive control each time. DAPK Z death-associated protein kinase; MGMT Z O6-methylguanine-DNA-
methyltranferase.
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to that of a study on Indian subjects,24 which found 87% of
overall hypermethylation in the three genes of oral cancer
tissues and 77% in adjacent tissues. Furthermore, our data
showed that p16, DAPK, and MGMT hypermethylation rates
in OSCC had CpG region frequencies of 67.2%, 45.3%, and
31.3% respectively, whereas p16, DAPK, and MGMT hyper-
methylation rates in adjacent tissues were 31.3%, 40.6%,
and 25.0% respectively. The adjacent tissues represent
clinically normal tissues with a high frequency of hyper-
methylation, which may indicate a molecular pathology,Table 2 Aberrant methylation patterns in different tissues.
Tissue specimens Gene
p16 DA
A
Normal 0% (0/20)
Adjacent normal tissue 31.3% (20/64) 40
OSCC 67.2% (43/64)a 45
B
OSCC (nonmetastasic) 63.0% (29/46) 41
OSCC (metastasic) 77.8% (14/18) 55
a The methylation rate of carcinoma tissues and corresponding non
b The methylation rate of carcinoma tissues with metastasis and no
DAPK Z death-associated protein kinase; MGMT Z O6-methylguaninei.e., epigenetic aberrations and a relatively higher risk of
progression toward malignant changes.
p16 is a tumor-suppressor gene that inhibits cyclin-
dependent kinase 4 and 6 activities and arrests the cell
cycle in the G1 phase. Aberrant methylation and mutation
of p16/MTS1 in OSCC of patients was found in our previous
study.36 Moreover, the frequency of hypermethylation of
p16 from the present study was 67.2%. This frequency is
much higher than that in other countries such as the US and
Japan, the frequencies of which are in the range of
21e47%.26e28 However, the hypermethylation frequency wePK MGMT GSTP1
0% (0/20) 0% (0/20) 0% (0/20)
.6% (26/64) 25% (16/64) 0% (0/64)
.3% (29/64) 31.3% (20/64) 0% (0/64)
.3% (19/46) 23.9% (11/46) 0
.6% (10/18)b 50% (9/18)b 0
tumorous tissue is statistically significant P < 0.05.
nmetastasis is statistically significant P < 0.05.
-DNA-methyltranferase; OSCC Z oral squamous cell carcinoma.
Table 3 Correlation of clinicopathological features and demographic characteristics with gene promoter hypermethylation in
primary oral tumors.
Number
of case (n)
Gene methylation Sign.
p16 No. (%) DAPK No. (%) MGMT No. (%)
Gender NS
Male 58 38 (65.5) 25 (43.1) 12 (20.7)
Female 6 5 (83.3) 4 (66.7) 1 (16.7)
Age NS
50 37 25 (67.6) 17 (45.9) 12 (32.4)
<50 27 18 (66.7) 10 (37.0) 0 (0)
Site NS
Buccal mucosa 32 24 (75.0) 14 (43.8) 8 (25.0)
Tongue 18 15 (62.5) 15 (62.5) 9 (37.5)
Other 8 5 (62.5) 1 (12.5) 3 (37.5)
Differentiation NS
Well 6 4 (66.7) 2 (33.3) 2 (33.3)
Well-Mod 18 9 (50.0) 6 (38.9) 5 (27.8)
Mod 34 26 (76.5) 17 (50.0) 2 (6.0)
Mod-poor, poor 6 4 (66.7) 1 (16.7) 4 (66.7)
Betel nut NS
þ 50 34 (68.0) 18 (36.0) 14 (28.0)
 14 10 (71.4) 10 (71.4) 5 (35.7)
Smoke NS
þ 50 33 (66.0) 20 (40.0) 17 (34.0)
 14 10 (71.4) 7 (50.0) 3 (21.4)
Alcohol NS
þ 40 27 (67.5) 18 (45.0) 10 (25.0)
 14 10 (71.4) 5 (35.7) 9 (35.7)
DAPK Z death-associated protein kinase; MGMT Z O6-methylguanine-DNA-methyltranferase; No. Z number; NS Z nonsignificant at
<0.05 level of significance for each of the genes; Sign. Z significance.
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ation of 66.7% among Indian subjects.24 These may be
caused by ethnic and gender differences. The loss of p16
through p16 promoter methylation in our patients may have
caused loss of function during tumor development. The
hypermethylation of p16 of the primary tumor was also
found to have slightly increased the metastasis rate in our
cancer patients, but we could not establish statistical
significance. This finding concurs with that of Maruya, who
reported that p16 is less likely to be related to lymph node
metastasis.31
Promoter hypermethylation of DAPK was also found in
45.3% of primary OSCC tissues in our study. This protein is
a mediator of apoptosis induced by interferon-g. Our
finding is similar to that of Sanchez-Cespedes et al.,25 who
observed a positive correlation between the methylation of
DAPK and the presence of lymph node metastases in
patients with head and neck cancer. We believe that
promoter hypermethylation of the DAPK gene can cause
potential metastasis in OSCC primary tumors.
Hypermethylation of MGMT in tumors with metastasis
was observed in our study.37 MGMT is a DNA repair protein
that removes adducts from O(6)alkyl G in DNA. If not
removed, adducts are mispaired with T[spell out?] duringDNA replication, resulting in G-to-A mutations. Thus, loss of
MGMT will cause increased mutation rates. Hyper-
methylation of MGMT is closely associated with point
mutations of K-ras at codons 12 and 13, lymph node inva-
sion, tumor stage, and disease-free survival.36 We found
a significant correlation between the methylation of MGMT
and the development of metastases.
The promoter region of the detoxifying gene, GSTP1, is
commonly hypermethylated in the promoter region in
prostate adenocarcinoma and hepatocellular carci-
noma,38,39 but it was not hypermethylated in either oral
cancer tissue, adjacent mucosa, or normal oral mucosa, as
previously reported.24 The regulation of GSTP1 expression
in OSCC might not occur through promoter methylation.
In summary, we concluded from our analysis that
a significant statistical correlation exists of aberrant
promoter hypermethylation patterns of one or more
cancer-related genes in primary tumors of oral carcino-
genesis and metastatic lesions. Our data support a number
of recent studies that detected gene promoter hyper-
methylation in the serum and sputum of patients with head
and neck tumors. Promoter hypermethylation may thus be
useful as a tumor marker for early diagnosis and disease
monitoring.
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